29.03.2017 • NewsElaine BurridgeSanofiSanofi Pasteur

MedImmune and Sanofi Pasteur in LRTI Drug Pact

(c) Astrazeneca
(c) Astrazeneca

AstraZeneca’s biologics R&D arm MedImmune and Sanofi’s vaccines division Sanofi Pasteur have agreed to develop and jointly commercialize the monoclonal antibody MEDI8897 for the treatment of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV).

This virus is the primary cause of LRTI among infants and young children. Most infants are infected before the age of one and virtually all get an RSV infection by the age of two, according to the US Centres for Disease Control and Prevention (CDC).

Under the terms of the agreement, Sanofi Pasteur will make an upfront payment of €120 million and pay up to €495 million upon achieving certain milestones. Both companies will lead all development activity through initial approvals and share all costs and profits equally. AstraZeneca will retain manufacturing activities for MEDI8897 while Sanofi Pasteur will lead commercialization efforts.

“By combining our development expertise and leadership in RSV with Sanofi Pasteur’s significant global experience in commercializing pediatric vaccines, we hope to provide an RSV disease prevention approach for all infants, both term and pre-term,” saidMedImmune’s executive vice president, Bahija Jallal. The treatment is being developed for the passive immunization of a broad infant population.

The drug is currently undergoing Phase IIb clinical trials in pre-term infants who are not eligible for MedImmune’s other RSV treatment Synagis, the only therapy currently approved for preventing LRTI caused by RSV in children at high risk. A Phase III trial is planned in healthy full-term and late pre-term infants. MEDI8897 has received fast track designation from the US Food & Drug Administration.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.